MERIDIAN, Idaho, Jan. 4 /PRNewswire-FirstCall/ -- RxElite, Inc. , a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today the suspension of their registration statement covering the resale of 53,747,555 shares. The suspension is permitted by the Securities and Exchange Commission in certain cases. The company requested this suspension to protect investors due to material non-public information relating to an acquisition. The Company will release information regarding the acquisition as soon as practical. The suspension of this registration statement is allowable for up to 90 days.
About RxElite, Inc.
RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
investorrelations@rxelite.com
CONTACT: Corporate Information of RxElite, Inc., +1-208-288-5550,
toll-free, 1-800-414-1901, fax, +1-208-288-1191; or Investor Relations,
Charlie Forshee of Segue Ventures LLC, +1-215-885-4981,
investorrelations@rxelite.com, for RxElite, Inc.
Web site: http://www.rxelite.com/
